The more investigators learn about the microbiome, the more it becomes clear that it impacts both disease development and treatment. Taconic Biosciences' Dr. Alexander Maue took an in-depth look at the microbiome's role in drug discovery in a three-part series for International Biopharmaceutical Industry. Part 1 explored the microbiome's impact on study reproducibility and translatability. Part 2 reviewed how the microbiome can alter therapeutic effectiveness and clinical outcomes. In this final installment, Dr. Maue discusses several novel models that leverage the microbiome to increase reproducibility and predictability:
“By tailoring the microbiome, investigators can utilize germ-free models associated with a minimal bacterial community. A minimal community would be helpful in evaluating potential therapies in a disease model dependent on having microbiota present, such as spontaneous colitis in an interleukin-10 deficient mouse.”
Read more at: biopharmaceuticalmedia.com
“By tailoring the microbiome, investigators can utilize germ-free models associated with a minimal bacterial community. A minimal community would be helpful in evaluating potential therapies in a disease model dependent on having microbiota present, such as spontaneous colitis in an interleukin-10 deficient mouse.”